Forasartan
Forasartan is an nonpeptide angiotensin AT1 receptor antagonist with an IC50 of 2.9 nM. Forasartan is also an anti-hypertension agent. Forasartan significantly inhibits preganglionic stimulation in a dose-dependent manner in vivo. Forasartan can inhibit the heart rate increase induced by angiotensin II.
For research use only. We do not sell to patients.
- CAS No.: 145216-43-9
- Formula: C23H28N8
- Molecular Weight:416.52
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Angiotensin Receptor Isoforms
More
Biological Activity
Description
Chemical Information
-
CAS No. 145216-43-9
-
Molecular Weight 416.52
-
Formula C23H28N8
-
SMILES
CCCCC1=NC(CCCC)=NN1CC2=CN=C(C3=CC=CC=C3C4=NNN=N4)C=C2
-
Synonyms
SC-52458
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
Purity & Documentation
References
[1]. Tokunaga, R., et al., (2001). Possible involvement of calcium-calmodulin pathways in the positive chronotropic response to angiotensin II on the canine cardiac sympathetic ganglia. Japanese journal of pharmacology, 86(4), 381-389. [Content Brief]
[2]. Gul, F., Parvaiz, N., & Azam, S. S. (2023). Deciphering the relational dynamics of AF-2 domain of PAN PPAR through drug repurposing and comparative simulations. PloS one, 18(3), e0283743. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)